Editas Medicine

Editas Medicine
Discovery-phase pharmaceutical company
Gene Editing
CRISPR Technology
Genomic Medicine
Clinical Research
Rare Diseases
Open roles at Editas Medicine
0 open roles
No open positions at this time
Closed positions
1 positions
Join Our Team
Remote
Closed 6d ago
Products and services

reni-cel
Gene Therapy
ED
EDIT-101
Gene Therapy
ED
EDIT-301
Cell Therapy
CR
CRISPR Gene Editing Platform
Technology Platform
ED
EDIT-201
Gene Therapy

In Vivo Gene Editing Medicines
Gene Therapy
ED
EDIT-103
Gene Therapy
IN
In Vivo Gene Editing Services
R&D Services
CR
CRISPR/Cas Gene Editing Platform
Platform Technology
EX
Ex Vivo Cell Engineering
R&D Services
EX
Ex Vivo Gene Editing Services
Research Services
EN
Engineered Natural Killer (eNK) Cell Platform
Cell Therapy
ED
EDIT-401
Gene Therapy
Leadership
CS
Charlene Stern
Executive Vice President & General Counsel
KB
Kevin Bitterman
Interim President
DRL
David R. Liu
Founder
FZ
Feng Zhang
Founder
Similar companies

Figure
AI robotics company
Toronto, Ontario, Canada
1-50 employees
Private
Valuation $2.6B
22 open jobs

Chewy
Internet retailer of pet items
Chennai, Tamil Nadu, India
1-50 employees
Public
Valuation $7.5B
270 open jobs

Equinox
American luxury fitness company
Newport Beach, California, United States
1-50 employees
Private

Teladoc
Leading company in the software industry
Purchase, New York, United States
5,001-10,000 employees
Public
Valuation $1.2B

Insulet
Multinational healthcare company.
Bedford, Massachusetts, United States
501-1,000 employees
Public
Valuation $2.1B
Latest updates
All
X
News
HN
YouTube
Form 144 Editas Medicine For: 22 July By Investing.com - Investing.com Canada
Investing.com Canada
News
·
2d ago
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
MarketBeat
News
·
2d ago
Editas Medicine (EDIT) insider plans to sell 5,500 shares after RSU vesting - Stock Titan
Stock Titan
News
·
3d ago
Editas Medicine (EDIT) 10K Form and Latest SEC Filings 2026 - MarketBeat
MarketBeat
News
·
3d ago
Exclusive: Genetic medicine startup launches to speed programs that stalled at Editas, Biogen - Endpoints News
Endpoints News
News
·
1 week ago
Show 15 more
Total Views
0
Total Apply Clicks
0
Total Mock Apply
0
Total Bookmarks
0
Reviews
4.2
5 reviews
Work-life balance
4.0
Compensation
3.5
Culture
4.3
Career
2.8
Management
3.5
78%
Recommend to a friend
Pros
Supportive and collaborative team environment
Great work-life balance and flexible hours
Cutting-edge research opportunities
Cons
Limited career advancement opportunities
High expectations and stress levels
Disorganized management practices
Salary Ranges
38 data points
Director
Junior/L3
Director
1 reports
$195,000
total per year
Base
$150,000
Stock
-
$195,000
$195,000
Interview experience
39 interviews
Difficulty
3.4
/ 5
Duration
2-5w
Offer rate
35%
Experience
Positive 67%
Neutral 15%
Negative 18%
Interview process
1
Phone Screen
2
Technical Interview
3
Hiring Manager
4
Team Fit
Contact and location